Inactive Instrument

Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Biotechnology & Medical Research

Satsuma Pharmaceuticals, Inc. Appoints Thomas M. Soloway to Its Board of Directors

July 07, 2020 at 09:01 pm

Satsuma Pharmaceuticals, Inc. announced that it has appointed Thomas M. Soloway to its Board of Directors effective July 2, 2020. Mr. Soloway currently serves as Executive Vice President and Chief Operating Officer of Audentes Therapeutics Inc.

Latest news about Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	01-18	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index	09/06/23	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index	09/06/23	CI
Insider Buy: Satsuma Pharmaceuticals	08/06/23	MT
Satsuma Pharmaceuticals, Inc. Announces CFO Changes	08/06/23	CI
Satsuma Pharmaceuticals, Inc. Announces CEO Changes	08/06/23	CI
Satsuma Pharmaceuticals, Inc. Announces Board Changes	08/06/23	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	07/06/23	CI
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review	18/05/23	MT
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101	18/05/23	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
North American Morning Briefing : Sentiment -3-	19/04/23	DJ
HC Wainwright Downgrades Satsuma Pharmaceuticals to Neutral From Buy	18/04/23	MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18/04/23	MT
Sector Update: Health Care Stocks Higher Premarket Monday	17/04/23	MT
Bank Earnings in Focus as US Equity Futures Tread Water	17/04/23	MT
Top Premarket Gainers	17/04/23	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	17/04/23	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	16/04/23	CI
Satsuma Pharmaceuticals Cash, Cash Equivalents and Marketable Securities Almost Halve to $52.5 Million at End of 2022	28/03/23	MT
Satsuma Pharmaceuticals Implements 36% Reduction in Workforce as Part of Cost-Cutting Program Shares Fall After Hours	28/03/23	MT
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/03/23	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	28/03/23	CI
Satsuma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	27/03/23	CI
North American Morning Briefing : Stock Futures -3-	27/03/23	DJ

Chart Satsuma Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs